Tirzepatide – 10 mg
Tirzepatide represents the cutting-edge of weight management research as a dual GLP-1/GIP receptor agonist. This innovative peptide demonstrates superior efficacy in clinical studies for significant weight reduction and metabolic optimization. Each 10mg vial provides pharmaceutical-grade purity (99%+) for advanced research applications.
| Quantity | Price | Discount |
|---|---|---|
| 2 | $106.70 | 3% |
| 5 | $103.40 | 6% |
| 10 | $97.90 | 11% |
| 11+ | $95.70 | 13% |
$110.00
What is Tirzepatide?
Tirzepatide is a novel dual-acting peptide that functions as both a
glucose-dependent insulinotropic polypeptide (GIP) receptor agonist
and a glucagon-like peptide-1 (GLP-1) receptor agonist.
This dual mechanism enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite.
Research shows Tirzepatide to be highly effective in lowering blood sugar levels and supporting significant weight reduction in type 2 diabetes and obesity studies.
Tirzepatide Structure
| Peptide Name | Tirzepatide |
|---|---|
| Synonyms | LY3298176 |
| Sequence | Pending detailed publication (synthetic 39 amino acid linear peptide analog) |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | ≈ 4813.5 g/mol |
Tirzepatide Research
1. Tirzepatide and Type 2 Diabetes
Clinical trials (SURPASS studies) have shown that Tirzepatide significantly reduces HbA1c levels compared to traditional GLP-1 receptor agonists. Patients experienced improvements in insulin sensitivity, fasting glucose, and overall glycemic control.
2. Tirzepatide and Obesity
Research demonstrates substantial weight reduction among non-diabetic participants. In one trial, subjects achieved up to a 20% decrease in body weight, making Tirzepatide one of the most effective anti-obesity peptides under investigation.
3. Cardiovascular Benefits
Emerging data suggests Tirzepatide may improve lipid profiles, reduce blood pressure, and lower inflammatory markers, supporting potential cardiovascular protective effects beyond glycemic control.
Future Tirzepatide Research
Ongoing studies are investigating Tirzepatide’s potential for long-term weight management, cardiovascular outcome benefits, and metabolic disease treatment beyond diabetes. Future areas of research may include fatty liver disease (NAFLD/NASH), combination therapies, and enhanced delivery systems for improved patient compliance.
Tirzepatide Resources
- Frias JP, et al. NEJM 2021 – “Tirzepatide versus Semaglutide in Type 2 Diabetes.”
- Jastreboff AM, et al. NEJM 2022 – “Tirzepatide Once Weekly for the Treatment of Obesity.”
- American Diabetes Association – Clinical trial summaries (SURPASS program).
Related Products
CJC-1295 w/ DAC – 5 mg (10 Vials/Kit)
Recently Viewed
Reviews
There are no reviews yet.